{"transactions":[{"id":745826,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-08T20:15:16.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":false,"shares":11580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 5, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 5, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11580},"source":{"system":"sec-edgar","filing":"0001590102-26-000002","document":"form4-06082026_040605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000159010226000002/form4-06082026_040605.xml","form_type":"4"}},{"id":745825,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-08T20:15:16.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":10987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":10987,"derivative":{"underlying":"Common Stock","underlying_shares":10987},"source":{"system":"sec-edgar","filing":"0001590102-26-000002","document":"form4-06082026_040605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000159010226000002/form4-06082026_040605.xml","form_type":"4"}},{"id":745824,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T20:15:16.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":42350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":42350,"derivative":{"exercise_price":4.71,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":42350},"source":{"system":"sec-edgar","filing":"0001590102-26-000002","document":"form4-06082026_040605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000159010226000002/form4-06082026_040605.xml","form_type":"4"}},{"id":745823,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:15:16.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":true,"shares":11580,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":726403,"source":{"system":"sec-edgar","filing":"0001590102-26-000002","document":"form4-06082026_040605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000159010226000002/form4-06082026_040605.xml","form_type":"4"}},{"id":970733,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-13T00:05:10.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 29, 2025, Merus N.V. (the \"Issuer\") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the \"Transaction Agreement\") with Genmab A/S (\"Genmab\") and its wholly owned subsidiary, Genmab Holding II B.V. (the \"Purchaser\"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the \"Shares\"), of the Issuer (the \"Offer\"), and, on December 12, 2025 (the \"Acceptance Time\"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the \"Offer Consideration\"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":13.35,"expiration_date":"2029-06-12","underlying":"Common Shares","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001193125-25-317964","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000119312525317964/ownership.xml","form_type":"4"}},{"id":970732,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-13T00:05:10.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4983,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 29, 2025, Merus N.V. (the \"Issuer\") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the \"Transaction Agreement\") with Genmab A/S (\"Genmab\") and its wholly owned subsidiary, Genmab Holding II B.V. (the \"Purchaser\"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the \"Shares\"), of the Issuer (the \"Offer\"), and, on December 12, 2025 (the \"Acceptance Time\"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the \"Offer Consideration\"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":23.3,"expiration_date":"2028-07-20","underlying":"Common Shares","underlying_shares":4983},"source":{"system":"sec-edgar","filing":"0001193125-25-317964","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000119312525317964/ownership.xml","form_type":"4"}},{"id":970731,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-13T00:05:10.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 29, 2025, Merus N.V. (the \"Issuer\") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the \"Transaction Agreement\") with Genmab A/S (\"Genmab\") and its wholly owned subsidiary, Genmab Holding II B.V. (the \"Purchaser\"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the \"Shares\"), of the Issuer (the \"Offer\"), and, on December 12, 2025 (the \"Acceptance Time\"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the \"Offer Consideration\"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":19.12,"expiration_date":"2027-05-24","underlying":"Common Shares","underlying_shares":5650},"source":{"system":"sec-edgar","filing":"0001193125-25-317964","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000119312525317964/ownership.xml","form_type":"4"}},{"id":970730,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-13T00:05:10.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 29, 2025, Merus N.V. (the \"Issuer\") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the \"Transaction Agreement\") with Genmab A/S (\"Genmab\") and its wholly owned subsidiary, Genmab Holding II B.V. (the \"Purchaser\"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the \"Shares\"), of the Issuer (the \"Offer\"), and, on December 12, 2025 (the \"Acceptance Time\"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the \"Offer Consideration\"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":10.04,"expiration_date":"2026-05-18","underlying":"Common Shares","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001193125-25-317964","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000119312525317964/ownership.xml","form_type":"4"}},{"id":970729,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-13T00:05:10.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8631,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 29, 2025, Merus N.V. (the \"Issuer\") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the \"Transaction Agreement\") with Genmab A/S (\"Genmab\") and its wholly owned subsidiary, Genmab Holding II B.V. (the \"Purchaser\"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the \"Shares\"), of the Issuer (the \"Offer\"), and, on December 12, 2025 (the \"Acceptance Time\"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the \"Offer Consideration\"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":16.09,"expiration_date":"2030-06-30","underlying":"Common Shares","underlying_shares":8631},"source":{"system":"sec-edgar","filing":"0001193125-25-317964","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000119312525317964/ownership.xml","form_type":"4"}},{"id":970728,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-13T00:05:10.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 29, 2025, Merus N.V. (the \"Issuer\") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the \"Transaction Agreement\") with Genmab A/S (\"Genmab\") and its wholly owned subsidiary, Genmab Holding II B.V. (the \"Purchaser\"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the \"Shares\"), of the Issuer (the \"Offer\"), and, on December 12, 2025 (the \"Acceptance Time\"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the \"Offer Consideration\"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":21.15,"expiration_date":"2031-05-28","underlying":"Common Shares","underlying_shares":6120},"source":{"system":"sec-edgar","filing":"0001193125-25-317964","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000119312525317964/ownership.xml","form_type":"4"}},{"id":970727,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-13T00:05:10.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 29, 2025, Merus N.V. (the \"Issuer\") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the \"Transaction Agreement\") with Genmab A/S (\"Genmab\") and its wholly owned subsidiary, Genmab Holding II B.V. (the \"Purchaser\"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the \"Shares\"), of the Issuer (the \"Offer\"), and, on December 12, 2025 (the \"Acceptance Time\"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the \"Offer Consideration\"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":18.56,"expiration_date":"2032-05-31","underlying":"Common Shares","underlying_shares":16604},"source":{"system":"sec-edgar","filing":"0001193125-25-317964","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000119312525317964/ownership.xml","form_type":"4"}},{"id":970726,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-13T00:05:10.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 29, 2025, Merus N.V. (the \"Issuer\") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the \"Transaction Agreement\") with Genmab A/S (\"Genmab\") and its wholly owned subsidiary, Genmab Holding II B.V. (the \"Purchaser\"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the \"Shares\"), of the Issuer (the \"Offer\"), and, on December 12, 2025 (the \"Acceptance Time\"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the \"Offer Consideration\"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":23.29,"expiration_date":"2033-06-08","underlying":"Common Shares","underlying_shares":14414},"source":{"system":"sec-edgar","filing":"0001193125-25-317964","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000119312525317964/ownership.xml","form_type":"4"}},{"id":970725,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-13T00:05:10.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8844,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 29, 2025, Merus N.V. (the \"Issuer\") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the \"Transaction Agreement\") with Genmab A/S (\"Genmab\") and its wholly owned subsidiary, Genmab Holding II B.V. (the \"Purchaser\"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the \"Shares\"), of the Issuer (the \"Offer\"), and, on December 12, 2025 (the \"Acceptance Time\"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the \"Offer Consideration\"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":48.73,"expiration_date":"2034-05-07","underlying":"Common Shares","underlying_shares":8844},"source":{"system":"sec-edgar","filing":"0001193125-25-317964","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000119312525317964/ownership.xml","form_type":"4"}},{"id":970724,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-13T00:05:10.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13193,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 29, 2025, Merus N.V. (the \"Issuer\") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the \"Transaction Agreement\") with Genmab A/S (\"Genmab\") and its wholly owned subsidiary, Genmab Holding II B.V. (the \"Purchaser\"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the \"Shares\"), of the Issuer (the \"Offer\"), and, on December 12, 2025 (the \"Acceptance Time\"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the \"Offer Consideration\"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option."}],"balance_after":0,"derivative":{"exercise_price":41.6,"expiration_date":"2035-05-22","underlying":"Common Shares","underlying_shares":13193},"source":{"system":"sec-edgar","filing":"0001193125-25-317964","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000119312525317964/ownership.xml","form_type":"4"}},{"id":1117452,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-09T20:20:24.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":false,"shares":4793,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 6, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 6, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4793},"source":{"system":"sec-edgar","filing":"0001415889-25-016250","document":"form4-06092025_040608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925016250/form4-06092025_040608.xml","form_type":"4"}},{"id":1117451,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-09T20:20:24.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":11580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":11580,"derivative":{"underlying":"Common Stock","underlying_shares":11580},"source":{"system":"sec-edgar","filing":"0001415889-25-016250","document":"form4-06092025_040608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925016250/form4-06092025_040608.xml","form_type":"4"}},{"id":1117450,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T20:20:24.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":42350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 5, 2025, subject to the Reporting Person's Continuous Service (as defined in the Plan) through each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":42350,"derivative":{"exercise_price":1.56,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":42350},"source":{"system":"sec-edgar","filing":"0001415889-25-016250","document":"form4-06092025_040608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925016250/form4-06092025_040608.xml","form_type":"4"}},{"id":1117449,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:20:24.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":true,"shares":4793,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":714823,"source":{"system":"sec-edgar","filing":"0001415889-25-016250","document":"form4-06092025_040608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925016250/form4-06092025_040608.xml","form_type":"4"}},{"id":1132938,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-05-27T12:00:07.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":13193,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest over a one-year period commencing on May 22, 2025 in 12 equal monthly installments."}],"balance_after":13193,"derivative":{"exercise_price":41.6,"expiration_date":"2035-05-22","underlying":"Common Shares","underlying_shares":13193},"source":{"system":"sec-edgar","filing":"0000950170-25-077383","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000095017025077383/ownership.xml","form_type":"4"}},{"id":1356939,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-20T21:20:04.000Z","date":"2024-11-19","kind":"purchase","planned":false,"acquired":true,"shares":666666,"price":2.25,"value":1499998.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock of the Issuer acquired from the Issuer pursuant to Rule 16b-3(d)."}],"balance_after":710030,"source":{"system":"sec-edgar","filing":"0001415889-24-027348","document":"form4-11202024_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924027348/form4-11202024_041101.xml","form_type":"4"}},{"id":1484518,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-10T20:15:11.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":4793,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy."}],"balance_after":4793,"derivative":{"underlying":"Common Stock","underlying_shares":4793},"source":{"system":"sec-edgar","filing":"0001415889-24-016192","document":"form4-06102024_040602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924016192/form4-06102024_040602.xml","form_type":"4"}},{"id":1484517,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-10T20:15:11.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":15750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest in twelve equal monthly installments commencing July 6, 2024, subject to Reporting Person's continuous service through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy."}],"balance_after":15750,"derivative":{"exercise_price":1.03,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":15750},"source":{"system":"sec-edgar","filing":"0001415889-24-016192","document":"form4-06102024_040602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924016192/form4-06102024_040602.xml","form_type":"4"}},{"id":1491463,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-04T20:30:12.000Z","date":"2024-06-01","kind":"exercise","planned":false,"acquired":false,"shares":4660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vested on June 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vested on June 1, 2024."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4660},"source":{"system":"sec-edgar","filing":"0001415889-24-015362","document":"form4-06042024_040606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924015362/form4-06042024_040606.xml","form_type":"4"}},{"id":1491462,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T20:30:12.000Z","date":"2024-06-01","kind":"exercise","planned":false,"acquired":true,"shares":4660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":43364,"source":{"system":"sec-edgar","filing":"0001415889-24-015362","document":"form4-06042024_040606.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924015362/form4-06042024_040606.xml","form_type":"4"}},{"id":1521832,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2024-05-09T20:30:27.000Z","date":"2024-05-07","kind":"grant","planned":false,"acquired":true,"shares":8844,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest over a one-year period commencing May 7, 2024 in 12 equal monthly installments."}],"balance_after":8844,"derivative":{"exercise_price":48.73,"expiration_date":"2034-05-07","underlying":"Common Shares","underlying_shares":8844},"source":{"system":"sec-edgar","filing":"0000950170-24-057084","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000095017024057084/ownership.xml","form_type":"4"}},{"id":1858341,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share option (right to buy)","published_at":"2023-06-12T20:14:09.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":14414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest over a one-year period commencing June 8, 2023 in 12 equal monthly installments."}],"balance_after":14414,"derivative":{"exercise_price":23.29,"expiration_date":"2033-06-08","underlying":"Common Shares","underlying_shares":14414},"source":{"system":"sec-edgar","filing":"0001209191-23-036263","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000120919123036263/doc4.xml","form_type":"4"}},{"id":1866236,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-05T20:45:45.000Z","date":"2023-06-02","kind":"exercise","planned":false,"acquired":false,"shares":4507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 2, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 2, 2023."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4507},"source":{"system":"sec-edgar","filing":"0001209191-23-034383","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123034383/doc4.xml","form_type":"4"}},{"id":1866235,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-05T20:45:45.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":4660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date."}],"balance_after":4660,"derivative":{"underlying":"Common Stock","underlying_shares":4660},"source":{"system":"sec-edgar","filing":"0001209191-23-034383","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123034383/doc4.xml","form_type":"4"}},{"id":1866234,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-05T20:45:45.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":15750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option will vest in twelve equal monthly installments commencing July 1, 2023, subject to Reporting Person's continuous service through each such date."}],"balance_after":15750,"derivative":{"exercise_price":8.7,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":15750},"source":{"system":"sec-edgar","filing":"0001209191-23-034383","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123034383/doc4.xml","form_type":"4"}},{"id":1866233,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T20:45:45.000Z","date":"2023-06-02","kind":"exercise","planned":false,"acquired":true,"shares":4507,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":38704,"source":{"system":"sec-edgar","filing":"0001209191-23-034383","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123034383/doc4.xml","form_type":"4"}},{"id":2241420,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-06T21:21:53.000Z","date":"2022-06-03","kind":"exercise","acquired":false,"shares":3356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 3, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 3, 2022."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3356},"source":{"system":"sec-edgar","filing":"0001209191-22-034589","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122034589/doc4.xml","form_type":"4"}},{"id":2241419,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-06T21:21:53.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":4507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date."}],"balance_after":4507,"derivative":{"underlying":"Common Stock","underlying_shares":4507},"source":{"system":"sec-edgar","filing":"0001209191-22-034589","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122034589/doc4.xml","form_type":"4"}},{"id":2241418,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-06T21:21:53.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":15750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date."}],"balance_after":15750,"derivative":{"exercise_price":14.48,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":15750},"source":{"system":"sec-edgar","filing":"0001209191-22-034589","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122034589/doc4.xml","form_type":"4"}},{"id":2241417,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-06T21:21:53.000Z","date":"2022-06-03","kind":"exercise","acquired":true,"shares":3356,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":34197,"source":{"system":"sec-edgar","filing":"0001209191-22-034589","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122034589/doc4.xml","form_type":"4"}},{"id":2246961,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share option (right to buy)","published_at":"2022-06-02T20:06:16.000Z","date":"2022-05-31","kind":"grant","acquired":true,"shares":16604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest over a one-year period commencing May 31, 2022 in 12 equal monthly installments."}],"balance_after":16604,"derivative":{"exercise_price":18.56,"expiration_date":"2032-05-31","underlying":"Common Shares","underlying_shares":16604},"source":{"system":"sec-edgar","filing":"0000899243-22-020671","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000089924322020671/doc4.xml","form_type":"4"}},{"id":2680481,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-05T00:00:23.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":3356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date."}],"balance_after":3356,"derivative":{"underlying":"Common Stock","underlying_shares":3356},"source":{"system":"sec-edgar","filing":"0001209191-21-038448","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121038448/doc4.xml","form_type":"4"}},{"id":2680480,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-05T00:00:23.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":12250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date."}],"balance_after":12250,"derivative":{"exercise_price":21.9,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":12250},"source":{"system":"sec-edgar","filing":"0001209191-21-038448","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121038448/doc4.xml","form_type":"4"}},{"id":2685829,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share option (right to buy)","published_at":"2021-06-02T20:10:28.000Z","date":"2021-05-28","kind":"grant","acquired":true,"shares":6120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest over a one-year period commencing May 28, 2021 in 12 equal monthly installments."}],"balance_after":6120,"derivative":{"exercise_price":21.15,"expiration_date":"2031-05-28","underlying":"Common Shares","underlying_shares":6120},"source":{"system":"sec-edgar","filing":"0000899243-21-021550","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000089924321021550/doc4.xml","form_type":"4"}},{"id":2880827,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option Grant (right to buy)","published_at":"2021-02-03T22:33:10.000Z","date":"2021-02-02","kind":"exercise","acquired":false,"shares":6632,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest in twelve equal monthly installments through June 29, 2017, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":0,"derivative":{"exercise_price":18.32,"expiration_date":"2026-06-28","underlying":"Common Stock","underlying_shares":6632},"source":{"system":"sec-edgar","filing":"0001209191-21-007377","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121007377/doc4.xml","form_type":"4"}},{"id":2880826,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option Grant (right to buy)","published_at":"2021-02-03T22:33:10.000Z","date":"2021-02-02","kind":"exercise","acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in twelve equal monthly installments through June 7, 2019, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":0,"derivative":{"exercise_price":18.35,"expiration_date":"2028-06-06","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-21-007377","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121007377/doc4.xml","form_type":"4"}},{"id":2880825,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-03T22:33:10.000Z","date":"2021-02-02","kind":"exercise","acquired":true,"shares":6632,"price":18.32,"value":121498.24,"ownership":{"direct":true},"balance_after":30841,"source":{"system":"sec-edgar","filing":"0001209191-21-007377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121007377/doc4.xml","form_type":"4"}},{"id":2880824,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-03T22:33:10.000Z","date":"2021-02-02","kind":"exercise","acquired":true,"shares":8000,"price":18.35,"value":146800.0,"ownership":{"direct":true},"balance_after":24209,"source":{"system":"sec-edgar","filing":"0001209191-21-007377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121007377/doc4.xml","form_type":"4"}},{"id":3090753,"issuer":{"id":70740,"kind":"organization","name":"Merus N.V.","symbol":"MRUS"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2020-07-02T20:00:32.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":8631,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest over a one-year period commencing June 30, 2020 in 12 equal monthly installments."}],"balance_after":8631,"derivative":{"exercise_price":16.09,"expiration_date":"2030-06-30","underlying":"Common Shares","underlying_shares":8631},"source":{"system":"sec-edgar","filing":"0001209191-20-040206","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000120919120040206/doc4.xml","form_type":"4"}},{"id":3118249,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-08T21:30:18.000Z","date":"2020-06-06","kind":"exercise","acquired":false,"shares":7333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"shares","element":"transactionShares","label":"F3","text":"This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vested on June 6, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vested on June 6, 2020."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7333},"source":{"system":"sec-edgar","filing":"0001209191-20-035033","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120035033/doc4.xml","form_type":"4"}},{"id":3118248,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option Grant (right to buy)","published_at":"2020-06-08T21:30:18.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject this option will vest in twelve equal monthly installments commencing July 4, 2020, subject to Reporting Person's continuous service through each such date."}],"balance_after":16500,"derivative":{"exercise_price":1.41,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001209191-20-035033","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120035033/doc4.xml","form_type":"4"}},{"id":3118247,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-08T21:30:18.000Z","date":"2020-06-06","kind":"exercise","acquired":true,"shares":7333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":16209,"source":{"system":"sec-edgar","filing":"0001209191-20-035033","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120035033/doc4.xml","form_type":"4"}},{"id":3226469,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2020-03-04T21:25:37.000Z","date":"2020-03-02","kind":"exercise","acquired":false,"shares":8876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest immediately."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest immediately."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8876},"source":{"system":"sec-edgar","filing":"0001209191-20-016081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120016081/doc4.xml","form_type":"4"}},{"id":3226468,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2020-03-04T21:25:37.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":8876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest immediately."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest immediately."}],"balance_after":8876,"derivative":{"underlying":"Common Stock","underlying_shares":8876},"source":{"system":"sec-edgar","filing":"0001209191-20-016081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120016081/doc4.xml","form_type":"4"}},{"id":3226467,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-04T21:25:37.000Z","date":"2020-03-02","kind":"exercise","acquired":true,"shares":8876,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":8876,"source":{"system":"sec-edgar","filing":"0001209191-20-016081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120016081/doc4.xml","form_type":"4"}},{"id":3338273,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-17T21:47:19.000Z","date":"2019-12-17","kind":"disposition_to_issuer","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option."}],"balance_after":0,"derivative":{"exercise_price":56.22,"expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000899243-19-029440","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000089924319029440/doc4.xml","form_type":"4"}},{"id":3338272,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-17T21:47:19.000Z","date":"2019-12-17","kind":"disposition_to_issuer","acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option."}],"balance_after":0,"derivative":{"exercise_price":50.93,"expiration_date":"2027-05-30","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0000899243-19-029440","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000089924319029440/doc4.xml","form_type":"4"}},{"id":3338271,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-17T21:47:19.000Z","date":"2019-12-17","kind":"disposition_to_issuer","acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option."}],"balance_after":0,"derivative":{"exercise_price":81.53,"expiration_date":"2028-05-29","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0000899243-19-029440","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000089924319029440/doc4.xml","form_type":"4"}},{"id":3338270,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-17T21:47:19.000Z","date":"2019-12-17","kind":"other","acquired":false,"shares":481270,"price":114.5,"value":55105415.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. (\"Spark\"), Roche Holdings, Inc. (\"Roche\") and 022019 Merger Subsidiary, Inc. (\"Merger Sub\") (the \"Merger Agreement\" and the transactions contemplated thereby, the \"Merger\"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are owned directly by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\"), the general partner of SVP VIII, and Anand Mehra, a director of the Issuer, James I. Healy, and Michael Powell, the managing members of SM VIII, may be deemed to have shared voting and dispositive power over the shares owned by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares owned by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-19-029440","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000089924319029440/doc4.xml","form_type":"4"}},{"id":3338269,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-17T21:47:19.000Z","date":"2019-12-17","kind":"other","acquired":false,"shares":40203,"price":114.5,"value":4603243.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. (\"Spark\"), Roche Holdings, Inc. (\"Roche\") and 022019 Merger Subsidiary, Inc. (\"Merger Sub\") (the \"Merger Agreement\" and the transactions contemplated thereby, the \"Merger\"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-19-029440","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000089924319029440/doc4.xml","form_type":"4"}},{"id":3365956,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-19T21:47:49.000Z","date":"2019-11-15","kind":"purchase","acquired":true,"shares":150000,"price":36.75,"value":5512500.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2671856,"source":{"system":"sec-edgar","filing":"0001104659-19-065582","document":"tm1923401-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000110465919065582/tm1923401-1_4.xml","form_type":"4"}},{"id":3374518,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":3,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2019-11-12T16:17:40.000Z","date":"2019-11-12","kind":"exercise","acquired":false,"shares":2709659,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":535869},"source":{"system":"sec-edgar","filing":"0000899243-19-027116","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924319027116/doc4.xml","form_type":"4"}},{"id":3374517,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":3,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2019-11-12T16:17:40.000Z","date":"2019-11-12","kind":"exercise","acquired":false,"shares":9090909,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1797843},"source":{"system":"sec-edgar","filing":"0000899243-19-027116","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924319027116/doc4.xml","form_type":"4"}},{"id":3374516,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":3,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-12T16:17:40.000Z","date":"2019-11-12","kind":"purchase","acquired":true,"shares":750000,"price":12,"value":9000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":3083712,"source":{"system":"sec-edgar","filing":"0000899243-19-027116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924319027116/doc4.xml","form_type":"4"}},{"id":3374515,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":3,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":4,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-12T16:17:40.000Z","date":"2019-11-12","kind":"exercise","acquired":true,"shares":2333712,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares reported herein are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Dr. Michael F. Powell, Dr. James Healy and Dr. Anand Mehra are the managing members of Sofinnova Management IX, L.L.C., the general partner of SVP IX, and as such, may be deemed to share voting and investment power with respect to such shares. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of such reporting person's pecuniary interest therein."}],"balance_after":2333712,"source":{"system":"sec-edgar","filing":"0000899243-19-027116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000089924319027116/doc4.xml","form_type":"4"}},{"id":3495348,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-06-10T21:47:23.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":7333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest on June 6, 2020, subject to the Reporting Person's continuous service with the issuer as of the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest on June 6, 2020, subject to the Reporting Person's continuous service with the issuer as of the vesting date."}],"balance_after":7333,"derivative":{"underlying":"Common Stock","underlying_shares":7333},"source":{"system":"sec-edgar","filing":"0001209191-19-035916","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919119035916/doc4.xml","form_type":"4"}},{"id":3504260,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-06-03T21:41:08.000Z","date":"2019-05-30","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On May 30, 2018, the reporting person was granted 1,500 restricted stock units that vest on the one-year anniversary of the grant date.  Vested shares are delivered to the reporting person on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On May 30, 2018, the reporting person was granted 1,500 restricted stock units that vest on the one-year anniversary of the grant date.  Vested shares are delivered to the reporting person on the vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001609351-19-000063","document":"wf-form4_155959805379521.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000160935119000063/wf-form4_155959805379521.xml","form_type":"4"}},{"id":3504259,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-03T21:41:08.000Z","date":"2019-05-30","kind":"exercise","acquired":true,"shares":1500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock."}],"balance_after":40203,"source":{"system":"sec-edgar","filing":"0001609351-19-000063","document":"wf-form4_155959805379521.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000160935119000063/wf-form4_155959805379521.xml","form_type":"4"}},{"id":3526046,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":3773585,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":469713},"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526045,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-3 Preferred Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":7301000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":908785},"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526044,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":3732500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":464599},"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526043,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":2239500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":278759},"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526042,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"purchase","acquired":true,"shares":400000,"price":15,"value":6000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2521856,"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526041,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":469713,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2121856,"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526040,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":908785,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":1652143,"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526039,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":464599,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":743358,"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3526038,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-15T17:59:51.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":278759,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":278759,"source":{"system":"sec-edgar","filing":"0001144204-19-026681","document":"tv521648_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420419026681/tv521648_4.xml","form_type":"4"}},{"id":3699830,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-08T21:30:38.000Z","date":"2019-01-04","kind":"exercise","acquired":false,"shares":37203,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on August 11, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are owned directly by Dr. Mehra."}],"balance_after":0,"derivative":{"exercise_price":3.45,"expiration_date":"2024-08-11","underlying":"Common Stock","underlying_shares":37203},"source":{"system":"sec-edgar","filing":"0001609351-19-000008","document":"wf-form4_154698301969473.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000160935119000008/wf-form4_154698301969473.xml","form_type":"4"}},{"id":3699829,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-08T21:30:38.000Z","date":"2019-01-04","kind":"exercise","acquired":true,"shares":37203,"price":3.45,"value":128350.35,"ownership":{"direct":true},"balance_after":38703,"source":{"system":"sec-edgar","filing":"0001609351-19-000008","document":"wf-form4_154698301969473.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000160935119000008/wf-form4_154698301969473.xml","form_type":"4"}},{"id":3784692,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-23T23:13:23.000Z","date":"2018-10-22","kind":"purchase","acquired":true,"shares":372093,"price":10.75,"value":3999999.75,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Such shares of the Company's Common Stock are owned by Sofinnova Venture Partners VIII, L.P. (\"Sofinnova VIII\"). The Reporting Person is a managing member of Sofinnova Management VIII, L.L.C., the general partner of Sofinnova VIII, and as such may be deemed to have shared voting and dispositive power over such shares with James I. Healy and Michael F. Powell, the other managing members of Sofinnova Management VIII, L.L.C. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein."}],"balance_after":1911573,"source":{"system":"sec-edgar","filing":"0001144204-18-055025","document":"tv505289_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000114420418055025/tv505289_form4.xml","form_type":"4"}},{"id":3801417,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche B Convertible Preferred Stock","published_at":"2018-10-02T21:41:14.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":9502249,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":458425},"source":{"system":"sec-edgar","filing":"0001209191-18-053539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000120919118053539/doc4.xml","form_type":"4"}},{"id":3801416,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche A Convertible Preferred Stock","published_at":"2018-10-02T21:41:14.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":7446904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":359267},"source":{"system":"sec-edgar","filing":"0001209191-18-053539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000120919118053539/doc4.xml","form_type":"4"}},{"id":3801415,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:41:14.000Z","date":"2018-09-28","kind":"purchase","acquired":true,"shares":337724,"price":15,"value":5065860.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein."}],"balance_after":1180178,"source":{"system":"sec-edgar","filing":"0001209191-18-053539","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000120919118053539/doc4.xml","form_type":"4"}},{"id":3801414,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:41:14.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":458425,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number includes an aggregate of 24,762 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein."}],"balance_after":842454,"source":{"system":"sec-edgar","filing":"0001209191-18-053539","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000120919118053539/doc4.xml","form_type":"4"}},{"id":3801413,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":2,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:41:14.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":359267,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. (\"SVP IX\"). Sofinnova Management IX, L.L.C. (\"SM IX\") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein."}],"balance_after":359267,"source":{"system":"sec-edgar","filing":"0001209191-18-053539","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000120919118053539/doc4.xml","form_type":"4"}},{"id":3810530,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":163491,"kind":"organization","name":"Sofinnova Venture Partners VIII, L.P.","position":1,"cik":"0001524064","reported_name":"Sofinnova Venture Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120371,"kind":"organization","name":"Sofinnova Management VIII, L.L.C.","position":2,"cik":"0001559565","reported_name":"Sofinnova Management VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-09-20T19:02:00.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":167537,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":167537},"source":{"system":"sec-edgar","filing":"0001209191-18-051838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919118051838/doc4.xml","form_type":"4"}},{"id":3810529,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":163491,"kind":"organization","name":"Sofinnova Venture Partners VIII, L.P.","position":1,"cik":"0001524064","reported_name":"Sofinnova Venture Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120371,"kind":"organization","name":"Sofinnova Management VIII, L.L.C.","position":2,"cik":"0001559565","reported_name":"Sofinnova Management VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-3 Preferred Stock","published_at":"2018-09-20T19:02:00.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":453954,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":453954},"source":{"system":"sec-edgar","filing":"0001209191-18-051838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919118051838/doc4.xml","form_type":"4"}},{"id":3810528,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":163491,"kind":"organization","name":"Sofinnova Venture Partners VIII, L.P.","position":1,"cik":"0001524064","reported_name":"Sofinnova Venture Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120371,"kind":"organization","name":"Sofinnova Management VIII, L.L.C.","position":2,"cik":"0001559565","reported_name":"Sofinnova Management VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2018-09-20T19:02:00.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":521235,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":521235},"source":{"system":"sec-edgar","filing":"0001209191-18-051838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919118051838/doc4.xml","form_type":"4"}},{"id":3810527,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":163491,"kind":"organization","name":"Sofinnova Venture Partners VIII, L.P.","position":1,"cik":"0001524064","reported_name":"Sofinnova Venture Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120371,"kind":"organization","name":"Sofinnova Management VIII, L.L.C.","position":2,"cik":"0001559565","reported_name":"Sofinnova Management VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2018-09-20T19:02:00.000Z","date":"2018-09-18","kind":"exercise","acquired":false,"shares":625482,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":625482},"source":{"system":"sec-edgar","filing":"0001209191-18-051838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919118051838/doc4.xml","form_type":"4"}},{"id":3810526,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":163491,"kind":"organization","name":"Sofinnova Venture Partners VIII, L.P.","position":1,"cik":"0001524064","reported_name":"Sofinnova Venture Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120371,"kind":"organization","name":"Sofinnova Management VIII, L.L.C.","position":2,"cik":"0001559565","reported_name":"Sofinnova Management VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T19:02:00.000Z","date":"2018-09-18","kind":"purchase","acquired":true,"shares":270000,"price":17,"value":4590000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":2038208,"source":{"system":"sec-edgar","filing":"0001209191-18-051838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919118051838/doc4.xml","form_type":"4"}},{"id":3810525,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":163491,"kind":"organization","name":"Sofinnova Venture Partners VIII, L.P.","position":1,"cik":"0001524064","reported_name":"Sofinnova Venture Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120371,"kind":"organization","name":"Sofinnova Management VIII, L.L.C.","position":2,"cik":"0001559565","reported_name":"Sofinnova Management VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T19:02:00.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":167537,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":1768208,"source":{"system":"sec-edgar","filing":"0001209191-18-051838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919118051838/doc4.xml","form_type":"4"}},{"id":3810524,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":163491,"kind":"organization","name":"Sofinnova Venture Partners VIII, L.P.","position":1,"cik":"0001524064","reported_name":"Sofinnova Venture Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120371,"kind":"organization","name":"Sofinnova Management VIII, L.L.C.","position":2,"cik":"0001559565","reported_name":"Sofinnova Management VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T19:02:00.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":453954,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":1600671,"source":{"system":"sec-edgar","filing":"0001209191-18-051838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919118051838/doc4.xml","form_type":"4"}},{"id":3810523,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":163491,"kind":"organization","name":"Sofinnova Venture Partners VIII, L.P.","position":1,"cik":"0001524064","reported_name":"Sofinnova Venture Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120371,"kind":"organization","name":"Sofinnova Management VIII, L.L.C.","position":2,"cik":"0001559565","reported_name":"Sofinnova Management VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T19:02:00.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":521235,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":1146717,"source":{"system":"sec-edgar","filing":"0001209191-18-051838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919118051838/doc4.xml","form_type":"4"}},{"id":3810522,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":163491,"kind":"organization","name":"Sofinnova Venture Partners VIII, L.P.","position":1,"cik":"0001524064","reported_name":"Sofinnova Venture Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120371,"kind":"organization","name":"Sofinnova Management VIII, L.L.C.","position":2,"cik":"0001559565","reported_name":"Sofinnova Management VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":5,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-09-20T19:02:00.000Z","date":"2018-09-18","kind":"exercise","acquired":true,"shares":625482,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held of record by Sofinnova Venture Partners VIII, L.P. (\"SVP VIII\"). Sofinnova Management VIII, L.L.C. (\"SM VIII\") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein."}],"balance_after":625482,"source":{"system":"sec-edgar","filing":"0001209191-18-051838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919118051838/doc4.xml","form_type":"4"}},{"id":3899547,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-08T20:00:44.000Z","date":"2018-06-07","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This grant was made pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest in twelve equal monthly installments through June 7, 2019, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":8000,"derivative":{"exercise_price":18.35,"expiration_date":"2028-06-06","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-18-036649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118036649/doc4.xml","form_type":"4"}},{"id":3910259,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-06-01T20:03:34.000Z","date":"2018-05-31","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On May 31, 2017, the reporting person was granted 1,500 restricted stock units that vest on the one-year anniversary of the grant date.  Vested shares are delivered to the reporting person on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On May 31, 2017, the reporting person was granted 1,500 restricted stock units that vest on the one-year anniversary of the grant date.  Vested shares are delivered to the reporting person on the vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001609351-18-000063","document":"wf-form4_152788335525922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000160935118000063/wf-form4_152788335525922.xml","form_type":"4"}},{"id":3910258,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-06-01T20:03:34.000Z","date":"2018-05-30","kind":"grant","acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the restricted stock units vest on the one-year anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"100% of the restricted stock units vest on the one-year anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date."}],"balance_after":1500,"derivative":{"underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001609351-18-000063","document":"wf-form4_152788335525922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000160935118000063/wf-form4_152788335525922.xml","form_type":"4"}},{"id":3910257,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-01T20:03:34.000Z","date":"2018-05-30","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares vest on the one-year anniversary of the grant date."}],"balance_after":4000,"derivative":{"exercise_price":81.53,"expiration_date":"2028-05-29","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001609351-18-000063","document":"wf-form4_152788335525922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000160935118000063/wf-form4_152788335525922.xml","form_type":"4"}},{"id":3910256,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-01T20:03:34.000Z","date":"2018-05-31","kind":"exercise","acquired":true,"shares":1500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock."}],"balance_after":1500,"source":{"system":"sec-edgar","filing":"0001609351-18-000063","document":"wf-form4_152788335525922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590102/000160935118000063/wf-form4_152788335525922.xml","form_type":"4"}},{"id":3914142,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"exercise","acquired":false,"shares":229660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Not applicable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":229660},"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":3914141,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"exercise","acquired":false,"shares":275446,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Not applicable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":275446},"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":3914140,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"exercise","acquired":false,"shares":721408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Not applicable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":721408},"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":3914139,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"purchase","acquired":true,"shares":500000,"price":13,"value":6500000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":1726514,"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":3914138,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"exercise","acquired":true,"shares":229660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":1226514,"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":3914137,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"exercise","acquired":true,"shares":275446,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":996854,"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}},{"id":3914136,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":147264,"kind":"organization","name":"Sofinnova Venture Partners IX, L.P.","position":1,"cik":"0001612133","reported_name":"Sofinnova Venture Partners IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":2,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":147265,"kind":"organization","name":"Sofinnova Management IX, L.L.C.","position":3,"cik":"0001612134","reported_name":"Sofinnova Management IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40389,"kind":"person","name":"Mehra Anand","position":4,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-30T21:59:25.000Z","date":"2018-05-30","kind":"exercise","acquired":true,"shares":721408,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Sofinnova Venture Partners IX, L.P. (the \"Fund\"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the \"GP\") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any."}],"balance_after":721408,"source":{"system":"sec-edgar","filing":"0001144204-18-031803","document":"tv495514_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612134/000114420418031803/tv495514_form4.xml","form_type":"4"}}],"next_cursor":"2018-05-30T21:59:25.000000Z,3914136"}